15105015D

HOUSE RESOLUTION NO. 242

Offered February 11, 2015

Memorializing the U.S. Food and Drug Administration to authorize clinical trials to determine the efficacy of using cannabidiol oil and THC-A oil for the treatment of epilepsy.

Patron—Marshall, R.G.

Referred to Committee on Rules

WHEREAS, cannabidiol oil or THC-A oil have been claimed to be effective for the treatment of epilepsy despite a lack of medical research to support such claim; and

WHEREAS, the American Academy of Neurology and the American Epilepsy Society both recognize the potential use of cannabidiol oil and THC-A oil for the treatment of epilepsy but note that there is insufficient evidence as to the efficacy of such oils; and

WHEREAS, the U.S. Food and Drug Administration has not authorized any significant clinical trials on the use of cannabidiol oil and THC-A oil for the treatment of epilepsy; now, therefore, be it

RESOLVED by the House of Delegates, That the U.S. Food and Drug Administration be urged to authorize clinical trials to determine the efficacy of using cannabidiol oil and THC-A oil for the treatment of epilepsy. In authorizing such clinical trials, the U.S. Food and Drug Administration should give due consideration to allowing the participation of willing medical schools or institutions of higher education located in the Commonwealth in such trials; and, be it

RESOLVED FURTHER, That the Clerk of the House of Delegates transmit copies of this resolution to the Speaker of the United States House of Representatives, the President of the United States Senate, the members of the Virginia Congressional Delegation, and the Commissioner of the U.S. Food and Drug Administration so that they may be apprised of the sense of the Virginia House of Delegates in this matter.

INTRODUCED